Literature DB >> 12093648

Thrombocytosis in patients with biopsy-proven giant cell arteritis.

Rod Foroozan1, Helen Danesh-Meyer, Peter J Savino, Greg Gamble, Omar N Mekari-Sabbagh, Robert C Sergott.   

Abstract

OBJECTIVE: To compare the platelet counts, complete blood counts, and Westergren sedimentation rates (WESR) of patients with a biopsy positive for giant cell arteritis (GCA) with those of patients with negative biopsies.
DESIGN: Retrospective, case-control series.
METHOD: The medical records of 91 consecutive patients who underwent temporal artery biopsy for possible GCA, over an 8-year period, were reviewed. MAIN OUTCOME MEASURES: Values obtained for the complete blood counts, including platelet counts, WESR, and biopsy results of 91 consecutive patients undergoing temporal artery biopsy were analyzed.
RESULTS: The mean platelet count of 47 patients with positive temporal artery biopsies (433 x 10(3)/microl) was significantly higher than that of 44 patients with negative temporal artery biopsies (277 x 10(3)/microl), P < 0.0001. There was no statistically significant difference in the mean WESR between the biopsy-positive (82 mm/hour) and biopsy-negative (70 mm/hour) groups, P = 0.12. The sensitivity of an elevated WESR for biopsy-positive patients was greater (79%; 95% confidence interval [CI], 64%-89%) than that of an elevated platelet count (57%; 95% CI, 42%-72%). However, the specificity (91% [95% CI, 78%-97%] versus 27% [95% CI, 15%-43%]), positive predictive value (87% [95% CI, 70%-96%] versus 54% [95% CI, 41%-66%]), and negative predictive value (67% [95% CI, 53%-78%] versus 55% [95% CI, 32%-76%]) favored an elevated platelet count compared with WESR, or to the combination of platelets and WESR, as a better test for diagnosing GCA in the 91 patients studied. The area under the receiver operating characteristic function for platelets (0.72) was greater than that for WESR (0.59) or the combination of platelets and WESR (0.65).
CONCLUSIONS: In patients suspected of having GCA, an elevated platelet count greater than 400 x 10(3)/microl is a useful marker of a positive temporal artery biopsy.

Entities:  

Mesh:

Year:  2002        PMID: 12093648     DOI: 10.1016/s0161-6420(02)01076-x

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  20 in total

Review 1.  Giant cell arteritis.

Authors:  J M Calvo-Romero
Journal:  Postgrad Med J       Date:  2003-09       Impact factor: 2.401

Review 2.  Neuro-Ophthalmological Emergencies.

Authors:  João Lemos; Eric Eggenberger
Journal:  Neurohospitalist       Date:  2015-10

Review 3.  Giant cell arteritis.

Authors:  Todd J Schwedt; David W Dodick; Richard J Caselli
Journal:  Curr Pain Headache Rep       Date:  2006-12

Review 4.  Giant cell arteritis.

Authors:  Xiang Wang; Zhi Ping Hu; Wei Lu; Xiang Q Tang; He P Yang; Liu W Zeng; Jie Zhang; Ting Li
Journal:  Rheumatol Int       Date:  2008-08-21       Impact factor: 2.631

5.  Giant cell arteritis.

Authors:  Michel J Belliveau; Martin W Ten Hove
Journal:  CMAJ       Date:  2011-02-07       Impact factor: 8.262

6.  The risk of deep venous thrombosis and pulmonary embolism in giant cell arteritis: a general population-based study.

Authors:  J Antonio Aviña-Zubieta; Vidula M Bhole; Neda Amiri; Eric C Sayre; Hyon K Choi
Journal:  Ann Rheum Dis       Date:  2014-09-29       Impact factor: 19.103

7.  Ocular pulse amplitude as a diagnostic adjunct in giant cell arteritis.

Authors:  P B Knecht; L M Bachmann; M A Thiel; K Landau; C Kaufmann
Journal:  Eye (Lond)       Date:  2015-06-19       Impact factor: 3.775

Review 8.  Review of Giant cell arteritis.

Authors:  Joseph G Chacko; J Anthony Chacko; Michael W Salter
Journal:  Saudi J Ophthalmol       Date:  2014-11-01

9.  Treatment of vision loss in giant cell arteritis.

Authors:  Ryan A Scheurer; Andrew R Harrison; Michael S Lee
Journal:  Curr Treat Options Neurol       Date:  2012-02       Impact factor: 3.598

10.  Occurrence of giant cell arteritis...suddenly.

Authors:  Brian R Younge; Cornelia M Weyand; Jorg J Goronzy
Journal:  Trans Am Ophthalmol Soc       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.